Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Irisin, two years later

dc.contributor.authorGarrido Novelle, Marta
dc.contributor.authorContreras Jiménez, Cristina
dc.contributor.authorRomero Picó, Amparo
dc.contributor.authorLópez, Miguel
dc.contributor.authorDiéguez, Carlos
dc.date.accessioned2024-01-23T17:45:11Z
dc.date.available2024-01-23T17:45:11Z
dc.date.issued2013
dc.descriptionThe research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under Grant agreement no. 281854—the ObERStress European Research Council Project(ML) and no. 245009—the Neurofast project (ML and CD), and Xunta de Galicia (ML: 10PXIB208164PR and 2012-CP070), Instituto de Salud Carlos III (ISCIII) (ML: PI12/01814), MINECO were co-funded by the FEDER Program of EU (CD:BFU2011-29102). CIBER de Fisiopatología de la Obesidad y Nutrición is an initiative of ISCIII.
dc.description.abstractIn January 2012, Boström and colleagues identified a new muscle tissue secreted peptide, which they named irisin, to highlight its role as a messenger that comes from skeletal muscle to other parts of the body. Irisin is a cleaved and secreted fragment of FNDC5 (also known as FRCP2 and PeP), a member of fibronectin type III repeat containing gene family. Major interest in this protein arose because of its great therapeutic potential in diabetes and perhaps also therapy for obesity. Here we review the most important aspects of irisin’s action and discuss its involvement in energy and metabolic homeostasis and whether the beneficial effects of exercise in these disease states could be mediated by this protein. In addition the effects of irisin at the central nervous system (CNS) are highlighted. It is concluded that although current and upcoming research on irisin is very promising it is still necessary to deepen in several aspects in order to clarify its full potential as a meaningful drug target in human disease states.
dc.description.departmentDepto. de Genética, Fisiología y Microbiología
dc.description.departmentDepto. de Fisiología
dc.description.facultyFac. de Ciencias Biológicas
dc.description.facultyFac. de Farmacia
dc.description.refereedTRUE
dc.description.sponsorshipInstituto de Salud Carlos III
dc.description.sponsorshipEuropean Commission
dc.description.sponsorshipXunta de Galicia
dc.description.statuspub
dc.identifier.citationNovelle, Marta G., et al. «Irisin, Two Years Later». International Journal of Endocrinology, vol. 2013, 2013, pp. 1-8. https://doi.org/10.1155/2013/746281.
dc.identifier.doi10.1155/2013/746281
dc.identifier.essn1687-8345
dc.identifier.issn1687-8337
dc.identifier.officialurlhttps://doi.org/10.1155/2013/746281
dc.identifier.urihttps://hdl.handle.net/20.500.14352/94891
dc.journal.titleInternational journal of endocrinology
dc.language.isoeng
dc.page.final8
dc.page.initial1
dc.publisherWiley
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.cdu577.17
dc.subject.ucmFarmacología (Medicina)
dc.subject.ucmMedicamentos
dc.subject.unesco2411.04 Fisiología Endocrina
dc.subject.unesco3206.10 Enfermedades de la Nutrición
dc.titleIrisin, two years later
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number2013
dspace.entity.typePublication
relation.isAuthorOfPublication2dbfe186-0df9-4fc5-9862-b6560eed3023
relation.isAuthorOfPublication57d03945-f13a-42ed-b7ae-11feb1ee1e56
relation.isAuthorOfPublication.latestForDiscovery2dbfe186-0df9-4fc5-9862-b6560eed3023

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Irisin.pdf
Size:
1.67 MB
Format:
Adobe Portable Document Format

Collections